Skip to main content
SpringerLink
Log in

FDG PET and PET/CT

  • Chapter
  • First Online:
Book cover Molecular Imaging in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 187))

Abstract

Molecular imaging with positron emission tomography (PET) using tumour-seeking radiopharmaceuticals has gained wide acceptance in oncology with many clinical applications. The hybrid imaging modality PET/CT allows assessing molecular as well as morphologic information at the same time. Therefore, PET/CT represents an efficient tool for whole body staging and re-staging within one imaging modality. In oncology the glucose analogue 18F-fluorodeoxyglucose (FDG) is the most widely used PET and PET/CT radiopharmaceutical in clinical routine. FDG PET and PET/CT have been used for staging and re-staging tumour patients in numerous studies. This chapter will discuss the use and the main indications of FDG PET and PET/CT in oncology with special emphasis on lung cancer, oesophageal cancer, colorectal cancer, head and neck cancer, lymphoma and breast cancer (among other tumour entities). A review of the current literature will be given with respect to primary diagnosis, staging and diagnosis of recurrent disease (local, lymph node and distant metastases). Besides its integral role in diagnosis, staging and re-staging of disease in oncology, there is increasing evidence that FDG PET and PET/CT can significantly contribute to therapy response assessment possibly influencing therapeutic management and treatment planning, to therapy tumour control and prediction of prognosis in oncologic patients, which will also be discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albers P, Bender H, Yilmaz H et al (1999) Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53(4):808–811

    Article  PubMed  CAS  Google Scholar 

  • Bastiaannet E, Groen H, Jager PL et al (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30(1):83–101

    Article  PubMed  CAS  Google Scholar 

  • Bertagna F, Biasiotto G, Orlando E et al (2010) Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol 28(9):629–636

    Article  PubMed  Google Scholar 

  • Birim O, Kappetein AP, Stijnen T et al (2005) Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79(1):375–382

    Article  PubMed  Google Scholar 

  • Brush J, Boyd K, Chappell F et al. (2011). The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 15(35): 1–192, iii-iv

    Google Scholar 

  • Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  • Czernin J, Benz MR, Allen-Auerbach MS (2010) PET/CT imaging: the incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol 73(3):470–480

    Article  PubMed  Google Scholar 

  • De Santis M, Becherer A, Bokemeyer C et al (2004) 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22(6):1034–1039

    Article  PubMed  Google Scholar 

  • Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A et al (2003) Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44(8):1301–1314

    PubMed  Google Scholar 

  • Duet M, Hugonnet F, Faraggi M (2010) Role of positron emission tomography (PET) in head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 127(1):40–45

    Article  PubMed  CAS  Google Scholar 

  • Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875–3876

    Article  PubMed  CAS  Google Scholar 

  • Essler M, Link A, Belloni B et al (2011) Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. PLoS ONE 6(9):e24632

    Article  PubMed  CAS  Google Scholar 

  • Fischer BM, Mortensen J, Hojgaard L (2001) Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2(11):659–666

    Article  PubMed  CAS  Google Scholar 

  • Fletcher C, Uni K, Meteus F (eds) (2002) World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Soft Tissue and Bone. IARC Press, Lyon

    Google Scholar 

  • Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49(3):480–508

    Article  PubMed  Google Scholar 

  • Forstner R, Sala E, Kinkel K et al (2010) ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 20(12):2773–2780

    Article  PubMed  Google Scholar 

  • Gould MK, Maclean CC, Kuschner WG et al (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285(7):914–924

    Article  PubMed  CAS  Google Scholar 

  • Gupta T, Master Z, Kannan S et al (2011) Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 38(11):2083–2095

    Article  PubMed  Google Scholar 

  • Hain SF, O’Doherty MJ, Timothy AR et al (2000) Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83(7):863–869

    Article  PubMed  CAS  Google Scholar 

  • Havrilesky LJ, Kulasingam SL, Matchar DB et al (2005) FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97(1):183–191

    Article  PubMed  Google Scholar 

  • Herrmann K, Benz MR, Krause BJ et al. (2012) F-18-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. Q J Nucl Med Mol Imaging: in press

    Google Scholar 

  • Herrmann K, Ott K, Buck AK et al (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48(12):1945–1950

    Article  PubMed  CAS  Google Scholar 

  • Heusner TA, Kuemmel S, Hahn S et al (2009) Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 36(10):1543–1550

    Article  PubMed  CAS  Google Scholar 

  • Hooft L, Hoekstra OS, Deville W et al (2001) Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86(8):3779–3786

    Article  PubMed  CAS  Google Scholar 

  • Huebner RH, Park KC, Shepherd JE et al (2000) A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41(7):1177–1189

    PubMed  CAS  Google Scholar 

  • Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in lymphoma. J Nucl Med 50(Suppl 1):21S–30S

    Article  PubMed  CAS  Google Scholar 

  • Jadvar H (2011) Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 52(1):81–89

    Article  PubMed  Google Scholar 

  • Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578

    Article  PubMed  Google Scholar 

  • Kubicek GJ, Champ C, Fogh S et al (2010) FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2:19

    Article  PubMed  Google Scholar 

  • Kwee TC, Kwee RM (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19(3):731–744

    Article  PubMed  Google Scholar 

  • Lv YL, Yuan DM, Wang K et al (2011) Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol 6(8):1350–1358

    Article  PubMed  Google Scholar 

  • Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206(2):475–481

    PubMed  CAS  Google Scholar 

  • Orlando LA, Kulasingam SL, Matchar DB (2004) Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 20(10):1063–1070

    Article  PubMed  CAS  Google Scholar 

  • Patnana M, Bronstein Y, Szklaruk J et al (2011) Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 66(3):224–236

    Article  PubMed  CAS  Google Scholar 

  • Reske SN (2009) PET and PET-CT of malignant tumors of the exocrine pancreas. Radiologe 49(2):131–136

    Article  PubMed  CAS  Google Scholar 

  • Ruf J, Lopez Hanninen E, Oettle H et al (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272

    Article  PubMed  Google Scholar 

  • Rusthoven KE, Koshy M, Paulino AC (2004) The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101(11):2641–2649

    Article  PubMed  Google Scholar 

  • Schick V, Franzius C, Beyna T et al (2008) Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging 35(10):1775–1785

    Article  PubMed  Google Scholar 

  • Schoder H, Herrmann K, Gonen M et al (2005) 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11(13):4761–4769

    Article  PubMed  Google Scholar 

  • Schreyogg J, Weller J, Stargardt T et al (2010) Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med 51(11):1668–1675

    Article  PubMed  Google Scholar 

  • Schwarz JK, Grigsby PW, Dehdashti F et al (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(Suppl 1):64S–73S

    Article  PubMed  CAS  Google Scholar 

  • Van den Abbeele AD (2008) The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8–13

    Article  PubMed  Google Scholar 

  • van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359(9315):1388–1393

    Article  PubMed  Google Scholar 

  • van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98(3):547–557

    Article  PubMed  Google Scholar 

  • van Westreenen HL, Westerterp M, Bossuyt PM et al (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22(18):3805–3812

    Article  PubMed  Google Scholar 

  • Viney RC, Boyer MJ, King MT et al (2004) Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22(12):2357–2362

    Article  PubMed  Google Scholar 

  • Wahl RL, Jacene H, Kasamon Y et al (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S

    Article  PubMed  CAS  Google Scholar 

  • Wu LM, Hu JN, Hua J et al (2012) 18F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Recurrent Gastric Cancer: A systematic review and meta-analysis. J Gastroenterol Hepatol 27(3):472–480

    Article  PubMed  CAS  Google Scholar 

  • Xie P, Li M, Zhao H et al (2011) 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 137(7):1085–1093

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Universitätsklinikum Rostock, Gertrudenplatz 1, 18057, Rostock, Germany

    Berud J. Krause & Sarah Schwarzenböck

  2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität, Munich, Germany

    Michael Souvatzoglou

Authors
  1. Berud J. Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Schwarzenböck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Souvatzoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berud J. Krause .

Editor information

Editors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany

    Otmar Schober

  2. Klinik für Nuklearmedizin, Universitätsklinikum Münster, Albert-Schweitzer-Str. 33, Münster, 48129, Germany

    Burkhard Riemann

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Krause, B.J., Schwarzenböck, S., Souvatzoglou, M. (2013). FDG PET and PET/CT. In: Schober, O., Riemann, B. (eds) Molecular Imaging in Oncology. Recent Results in Cancer Research, vol 187. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10853-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-10853-2_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-10852-5

  • Online ISBN: 978-3-642-10853-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation